Business Description
Anbio Biotechnology
ISIN : KYG0367B1059
Share Class Description:
NNNN: Class ATotal Employee Number:
27Description
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 1 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3732.03 | |||||
Beneish M-Score | 1.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.5 | |||||
3-Year EBITDA Growth Rate | 23.5 | |||||
3-Year EPS without NRI Growth Rate | 24.2 | |||||
3-Year Book Growth Rate | 33.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.49 | |||||
9-Day RSI | 25.69 | |||||
14-Day RSI | 28.66 | |||||
3-1 Month Momentum % | 24.26 | |||||
6-1 Month Momentum % | 8.96 | |||||
12-1 Month Momentum % | -11.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 343.67 | |||||
Quick Ratio | 343.67 | |||||
Cash Ratio | 135.24 | |||||
Days Sales Outstanding | 118.71 | |||||
Days Payable | 238.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -1.32 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 87.23 | |||||
Operating Margin % | 66.69 | |||||
Net Margin % | 74.06 | |||||
EBITDA Margin % | 66.69 | |||||
FCF Margin % | 17.13 | |||||
OCF Margin % | 17.13 | |||||
ROE % | 25.65 | |||||
ROA % | 25 | |||||
ROIC % | 45.68 | |||||
3-Year ROIIC % | -30.8 | |||||
ROC (Joel Greenblatt) % | 46.24 | |||||
ROCE % | 23.1 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 84.76 | |||||
PE Ratio without NRI | 92.3 | |||||
PS Ratio | 62.61 | |||||
PB Ratio | 18.14 | |||||
Price-to-Tangible-Book | 18.06 | |||||
Price-to-Free-Cash-Flow | 366.47 | |||||
Price-to-Operating-Cash-Flow | 366.47 | |||||
EV-to-EBIT | 92.77 | |||||
EV-to-EBITDA | 92.77 | |||||
EV-to-Revenue | 61.87 | |||||
EV-to-FCF | 361.23 | |||||
Price-to-Graham-Number | 8.65 | |||||
| Price-to-Net-Current-Asset-Value | 18.06 | |||||
| Price-to-Net-Cash | 46.15 | |||||
Earnings Yield (Greenblatt) % | 1.08 | |||||
FCF Yield % | 0.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NNNN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anbio Biotechnology Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.647 | ||
| EPS (TTM) ($) | 0.147 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 117.38 | ||
| 14-Day RSI | 28.66 | ||
| 14-Day ATR ($) | 2.518461 | ||
| 20-Day SMA ($) | 16.38225 | ||
| 12-1 Month Momentum % | -11.27 | ||
| 52-Week Range ($) | 10.5 - 55.65 | ||
| Shares Outstanding (Mil) | 43.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anbio Biotechnology Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anbio Biotechnology Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 132 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 38 days | ||
| General meeting for 2025 | 2026-07-20 | In 16 days | ||
| First quarter earnings results for 2026 | 2026-07-06 | In 2 days | ||
| Annual report for 2025 | 2026-04-07 | 26.15 (-0.97%) | ||
| Annual report for 2024 | 2025-04-28 | 6.53 (-3.55%) |
Show
Entries
Anbio Biotechnology Frequently Asked Questions
What is Anbio Biotechnology(NNNN)'s stock price today?
The current price of NNNN is $12.46. The 52 week high of NNNN is $55.65 and 52 week low is $10.50.
When is next earnings date of Anbio Biotechnology(NNNN)?
The next earnings date of Anbio Biotechnology(NNNN) is 2026-07-06 Est..
Does Anbio Biotechnology(NNNN) pay dividends? If so, how much?
Anbio Biotechnology(NNNN) does not pay dividend.
Guru Commentaries on NAS:NNNN
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Anbio Biotechnology
No articles.
Headlines
See More- 1
Jun 18, 2026
Top 3 Health Care Stocks You'll Regret Missing In Q2
Benzinga • 5:02am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers